Trial Profile

A Phase 1b, Open-Label Parallel Study Evaluating CLR 125 in Patients With Relapsed or Refractory Triple Negative Breast Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 16 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CLR 121125 (Primary) ; Iopofosine I 131 (Primary)
Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
Focus Adverse reactions
Sponsors Cellectar Biosciences

14 Apr 2026 According to Cellectar Biosciences media release, the first patient has been enrolled in this trial. Additional study sites being activated in Q2, plan to provide dosimetry, safety, and efficacy updates throughout 2026.
09 Jan 2026 According to Cellectar Biosciences media release, Anticipates Dosing of First Patients in Phase 1b Study of CLR 125 for the Treatment of Triple Negative Breast Cancer in 1Q26 with Interim Data Mid-2026
06 Jan 2026 New source identified and integrated(ClinicalTrials.gov: US National Institutes of Health;NCT07311993)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com